These 3 High-Yield Stocks Have Been Growing Their Dividends Non-Stop, And Analysts Expect Their Share Prices To Climb Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Income-seeking investors are always on the lookout for reliable high-yield stocks with a history of consistent dividend growth. Three companies that fit this bill are Federal Realty Investment Trust (NYSE:FRT), Realty Income Corp. (NYSE:O), and Pfizer Inc. (NYSE:PFE). Not only have these companies been increasing their dividends for years, but analysts also expect their share prices to climb in the near future. Federal Realty Investment Trust: A Dividend King with 56 Years of Consecutive Growth Federal Realty Investment Trust is a recognized leader in the ownership, operation, and redevelopment of high-quality retail-based properties located primarily in major coastal markets across the United States. With a portfolio spanning 102 properties, approximately 3,300 tenants and 26 million commercial square feet, Federal Realty has demonstrated its expertise in creating unique and vibrant environments that combine shopping, dining, living and working. What sets Federal Realty apart is its impressive track record of dividend growth. The company has increased its quarterly dividends to shareholders for 56 consecutive years, the longest streak in the REIT industry. This achievement has earned Federal Realty the prestigious title of a Dividend King. Currently, the stock offers a 4.27% yield, with a quarterly dividend of $1.09 per share. Analysts are bullish on Federal Realty’s future prospects, with a consensus price target of $117.04 based on the 74 latest ratings. The most recent analyst ratings from Deutsche Bank, B of A Securities and Truist Securities suggest an average price target of $117, implying a 13.31% upside potential. Realty Income Corp: The Monthly Dividend Company Realty Income, an S&P 500 company, is a real estate partner to the world’s leading companies. Founded in 1969, the company invests in diversified commercial real estate and boasts a portfolio of over 15,450 properties across all 50 U.S. states and seven countries in Europe. Known as “The Monthly Dividend Company,” Realty Income has a mission to deliver stockholders dependable monthly dividends that grow over time. Realty Income has declared 646 consecutive monthly dividends and is a member of the S&P 500 Dividend Aristocrats index, having increased its dividend for the last 25 consecutive years. The stock currently offers a 5.74% yield, with a monthly dividend of $0.2570 per share and a 5-year dividend growth rate (CAGR) of 3.59%. Analysts have a consensus price target of $56.53 for Realty Income, based on the 51 latest ratings. Recent analyst ratings from Mizuho, Stifel and BMO Capital suggest an average price target of $59.33, implying an 8.97% upside potential. Pfizer Inc: A Pharmaceutical Giant with 13 Years of Consecutive Dividend Growth Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, markets, distributes and sells medicines and vaccines in various therapeutic areas. The company’s portfolio includes well-known brands such as Eliquis, Prevnar, Comirnaty and Paxlovid. Pfizer has been increasing its dividends for 13 consecutive years, with a 5-year dividend growth rate (CAGR) of 4.77%. The stock currently offers a 6.61% yield, with a quarterly dividend of $0.42 per share. Analysts have a consensus price target of $40.54 for Pfizer, based on the 100 latest ratings. Recent analyst ratings from Cantor Fitzgerald suggest an average price target of $45, implying a significant 74.89% upside potential. Looking For Reliable High Yield? Consider This Alternative Approach While the above-mentioned high-yield stocks offer attractive income opportunities, investors seeking to diversify their portfolios and mitigate market volatility risks might consider an alternative approach: the Cityfunds Yield fund. The Cityfunds Yield fund targets an 8% APY and provides investors with stable cash flow backed by real estate assets. Investors receive quarterly distributions, which can be reinvested into the fund to compound returns or paid out to their bank account. The fund has a five-year term and options for redemption after 12 months. The Yield fund invests in a diversified pool of collateralized real estate loans through two asset types: 1. Home Equity-Backed Notes issued to Cityfunds I, LLC (Series funds), Cityfunds Portfolio Fund, LLC, and Nada Investments, LLC (collectively, “HEI Borrowers”). These notes have 3-year terms, earn an interest rate of 8% to 9%, and are secured by a UCC lien filed against the specific home equity investment agreement real estate assets held by the respective HEI borrower as collateral. 2. Short-term Mortgage Notes originated and serviced by third parties, with typical terms of 3 to 5 years and interest rates of 9% to 12% fixed per annum. These mortgages are secured by a deed of trust or mortgage type of lien filed with the county clerk of the specific property’s county. The Cityfunds Yield fund offers investors a manager-guaranteed base yield of 7% and a target of 8%, making it an attractive option for those seeking reliable high-yield income streams backed by real estate assets. See how much you could be earnings with the Cityfunds Yield fund. While Federal Realty Investment Trust, Realty Income Corp. and Pfizer Inc. offer compelling opportunities for income-seeking investors, it’s essential to consider alternative approaches like the Cityfunds Yield fund to diversify one’s portfolio and potentially mitigate market risks. As always, investors should conduct thorough research and consult with a financial advisor before making any investment decisions. This article These 3 High-Yield Stocks Have Been Growing Their Dividends Non-Stop, And Analysts Expect Their Share Prices To Climb originally appeared on Benzinga.com
These 3 High-Yield Stocks Have Been Growing Their Dividends Non-Stop, And Analysts Expect Their Share Prices To Climb
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...